Douglas V. Faller, MD, PhD

Professor, Medicine

Douglas Faller
72 E. Concord St Silvio Conte (K)


Dr. Douglas Faller is a Boston-based physician/scientist with over 15 years of pharmaceutical and biotech experience involving discovery, pre-clinical and clinical development of small molecules for several therapeutic areas, specializing in oncology and hematology, plus over 25 years of academic clinical and laboratory research experience in the fields of drug discovery and development, oncology and hematology, cell and molecular biology, management of professionals, including the programmatic organization of large groups of scientists, and development of research and drug development programs.

Other Positions

  • Active Staff Privileges, Hematology & Medical Oncology, Medicine, Boston Medical Center


  • Harvard University, MD
  • Massachusetts Institute of Technology, PhD
  • Massachusetts Institute of Technology, BS


  • Published on 12/7/2018

    Faller DV. Response to "Selective PKCd inhibitor B106 elicits uveal melanoma growth inhibitory effects independent of activated PKC isoforms". ACS Chem Biol. 2018 Dec 07. PMID: 30525445.

    Read at: PubMed
  • Published on 10/15/2018

    Bell JA, Galaznik A, Blazer M, Shih HC, Farrelly E, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV. Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States. Pharmacoecon Open. 2018 Oct 15. PMID: 30324565.

    Read at: PubMed
  • Published on 7/1/2018

    Moos WH, Faller DV, Glavas IP, Harpp DN, Irwin MH, Kanara I, Pinkert CA, Powers WR, Steliou K, Vavvas DG, Kodukula K. A New Approach to Treating Neurodegenerative Otologic Disorders. Biores Open Access. 2018; 7(1):107-115. PMID: 30069423.

    Read at: PubMed
  • Published on 6/22/2018

    Bell JA, Galaznik A, Blazer M, Farrelly E, Ogbonnaya A, Raju A, Eaddy M, Fram RJ, Faller DV. Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care. Leuk Lymphoma. 2018 Jun 22; 1-11. PMID: 29932781.

    Read at: PubMed
  • Published on 6/18/2018

    Bell JA, Galaznik A, Farrelly E, Blazer M, Murty S, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV, Kota V. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. Leuk Res. 2018 Aug; 71:27-33. PMID: 29944984.

    Read at: PubMed
  • Published on 5/21/2018

    Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. Invest New Drugs. 2018 May 21. PMID: 29781056.

    Read at: PubMed
  • Published on 5/10/2018

    Bell JA, Galaznik A, Huelin R, Stokes M, Guo Y, Fram RJ, Faller DV. Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review. Clin Lymphoma Myeloma Leuk. 2018 Jul; 18(7):e303-e314. PMID: 29802009.

    Read at: PubMed
  • Published on 2/8/2018

    Bell JA, Galaznik A, Huelin R, Stokes M, Guo Y, Fram RJ, Faller DV. Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2018 Apr; 18(4):e157-e166. PMID: 29475821.

    Read at: PubMed
  • Published on 1/18/2018

    Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W, Vardhanabhuti S, Pawlikowska-Dobler I, Faessel HM, Dash AB, Sedarati F, Dezube BJ, Faller DV, Savona MR. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 2018 Mar 29; 131(13):1415-1424. PMID: 29348128.

    Read at: PubMed
  • Published on 1/5/2018

    Hari P, Lin HM, Asche CV, Ren J, Yong C, Luptakova K, Faller DV, Sanchorawala V. Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis. Amyloid. 2018 Mar; 25(1):1-7. PMID: 29303358.

    Read at: PubMed

View 273 more publications: View full profile at BUMC

View all profiles